MINNEAPOLIS & ORLANDO, Fla.--(BUSINESS WIRE)--CVRx announced today that longer-term data from early Rheos clinical studies show significant reductions in hypertension and improvements in heart structure and function. The Rheos® Hypertension System, developed by the Minneapolis-based company, is the first device designed to treat hypertension, a leading cause of heart and kidney disease, stroke and death. The Rheos System activates the carotid baroreflex, the body’s own system for regulating blood pressure, and may provide a future treatment option for the millions of people who cannot control their high blood pressure (hypertension) with medications.
